ABSTRACT Alternating purine-pyrimidine sequences (RY repeats) demonstrate considerable homology to the consensus sequence for vertebrate topoisomerase 11 ) Nucleic Acids Res. 16: 1533-1556. This is shown below and positions that can match are underscored. RYRYRYRYRYRYRYRYRY = alternating purine-RNYNNCNNGYNGKTNYNY pyrimidine 18 bp = topoisomerase 11 consensus sequence (R is purine, Y is pyrimidine, K is G or T.) Topoisomerase 11 cleavage reactions were performed (in the absence of inhibitors) on a plasmid containing a 54 base RY repeat and the single strong cleavage site mapped to the RY repeat. Analysis of this DNA on sequencing gels showed that the enzyme cleaved a number of sites, all within the 54 base pair RY repeat. Topoisomerase 11 also made clustered cleavages within other RY repeats that were examined. Quantitative analysis of homology to the consensus sequence, as measured by the match of a site to a matrix of base proportions from the consensus data base (the matrix mean), showed that both the locations and the frequencies of cleavage sites within RY repeats were proportional to homology scores. However, topoisomerase 11 cleaved RY repeats preferentially in comparison to non-RY sites with similar homology scores. The activity of the enzyme at RY repeats appears to be proportional to the length of the repeat; additionally, GT, AC and AT repeats were better substrates for cleavage than GC repeats. INTRODUCTION DNA topoisomerases transiently break and then reseal the DNA helix, altering DNA linking number and allowing adjustment of topology. Topoisomerases have been implicated in many important cellular processes (see 1,2 for reviews); in particular,
INTRODUCTION DNA topoisomerases transiently break and then reseal the DNA helix, altering DNA linking number and allowing adjustment of topology. Topoisomerases have been implicated in many important cellular processes (see 1,2 for reviews); in particular, topoisomerase II is a major component of the nuclear matrix/chromosome scaffold (3) (4) (5) , it is required for completion of mitosis in yeast (6) (7) (8) (9) and subject to cell-cycle regulation (10) . To investigate further the cellular role of topoisomerase II, we previously characterized catalytic sites of vertebrate topoisomerase II and derived the following consensus sequence:
5'RNYNCNGY NGKTNYNY3'
where R is purine, Y is pyrimidine, K is G or T, N is any base, and cleavage occurs at the caret (^) (11) . The topoisomerase II consensus sequence is distributed nonrandomly in eukaryotic DNA and is frequently found in or near transcriptional enhancers (11) . We also recognized that any sequence containing alternating purines and pyrimidines matches the consensus sequence quite well (see Table 1 ) and in the present study, we report on the reactivity of topoisomerase II to alternating purine-pyrimidine DNA. Alternating purine-pyrimidine sequences (which we refer to as RY repeats) have been identified in naturally occurring DNA and have intriguing properties. Certain RY repeats have been found to exist as non-B form DNA (Z-DNA, cruciforms) (12, 13) and may have significant biological consequences by affecting protein binding at RY repeats (14) and proximal sequences (15) . Long RY repeats are highly recombinagenic in bacterial hosts (14, (16) (17) (18) (19) and frequently result in deletions. Additionally, lesions in RY repeats are not efficiently processed by DNA repair machinery (20, 21) . In three human fetal globin genes the second intervening sequence contains large RY repeats (40-60 bp) which can adopt the Z-DNA conformation in vitro and which are hotspots for recombination and gene conversion in vivo (22) . Furthermore, there is a long RY repeat about 550 bp upstream of the human (-globin translation start which is also a hotspot for recombination (23) , and mutations in this region are conservative, that is, they maintain the RY repeat. Finally, proteins that specifically bind (CG)n DNA have been identified from Drosophila, SV40 minichromosomes, and wheat germ (24) (25) (26) . We show in this report that topoisomerase II is extremely reactive towards RY repeat sequences; therefore, topoisomerase II is also a eukaryotic DNA binding protein that preferentially recognizes alternating purine-pyrimidine DNA. Table 1 . Match of (GC), and (GT)h to the topoisomerase 11 consensus sequence. A. Match of (GC), to the topoisomerase 11 consensus sequenceb 
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a The site of topoisomerase 11 cleavage is marked at the arrows."N" indicates that no nucleotide is preferred at the position, R is purine, Y is pyrmidine and K is G or T. The consensus sequence is from Spitzner and Muller (1988) .
b (GC),, is cleaved weakly by topoisomerase 11, whereas (GT)n is cleaved much more frequently (see Figs. 4 and 5). c The "Matrix Mean" corresponds to the sum of nucleotide proportions of all non-N positions in the data base divided by 20 (see Table 4 and Methods). (11, 27, 30) . It is clear that the consensus sequence has a degree of alternating purinepyrimidine (or RY) character, and further that specific examples of RY repeats show considerable homology to the consensus sequence (see Table 1 ). (23) . The RY repeat was subcloned into pUC19 to produce pRYG (see Methods and Table 2 below for sequence). Topoisomerase H cleavage reactions were performed on either supercoiled or relaxed pRYG using the purified chicken enzyme (30) , and the DNA was repurified and digested with appropriate restriction enzymes. Cleavage sites were identified by indirect end labeling using two different probes. In all cases, a single strong cleavage band (arrows, Figure 1 ) was detected at the 54 base RY repeat. The intensity of the band was roughly proportional to the amount of enzyme added. The topology of the plasmid (supercoiled or relaxed) did not seem to affect the results (however, the presence of ATP would allow relaxation of the supercoiled substrate). In pRYG, the RY repeat was clearly the preferred topoisomerase II site compared to any of the other potential 3000 or so sites. The results of this experiment were confirmed using different restriction enzymes and different probes to verify that the cleavage site was correctly localized at the RY repeat (data not shown). The experiment shown in Fig. 1 was also repeated in the presence of the topoisomerase II inhibitors Fig. 2A ) within the fragment. While the sites and strengths of VM26 enhanced cleavages were not identical to those with the enzyme alone or with m-AMSA added (the latter two showed the same strong sites), the trend was generally the same: the enzyme made an array of cleavages within the RY repeat. Cleavages were also mapped on the opposite strand of the RY repeat of pRYG. As indicated in Table 2 , the cleavages on this bottom strand were very similar to the pattern observed for the top strand, suggesting that most of the cleavages were indeed double strand events with a 4 base 5' overhang, as expected for topoisomerase II. There were several exceptions where unequal cleavage frequencies were detected between the two strands at a site as reported previously (30) . The data show that the strong cleavage band detected by indirect end labeling was in reality a cluster of proximal cleavage sites. This conclusion was further supported by data from mapping the topoisomerase II sites on the whole plasmid by primer extension: sites mapped by primer extension of an end labeled oligonucleotide coincided with sites observed in Fig. 2 Topoisomerase II cleavages were performed on a fragment from pCGTA-C (28), which contains the RY repeat (CG)6TA(CG)6 (Fig. 4) . The enzyme was clearly less reactive towards this sequence than to the previous RY repeats and this was predicted by the lower topoisomerase LI matrix mean score of a GC repeat compared to the matrix means for GT or AT repeats (see Tables 1 and 4 ). However, the cleavage sites on the pCGTA-C fragment were still within the RY repeat, supporting the hypothesis that alternating purine-pyrimidine sequences are preferentially recognized by topoisomerase LI. The results of this experiment and others (not shown) revealed that topoisomerase II was generally much less reactive to GC repeats compared to other RY repeats, especially in the absence of the drugs (see Fig.  4 , lane 3). In the presence of VM26 and m-AMSA, additional, stronger cleavage sites within the RY repeat were observed (lanes 1, 2).
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As noted above, (GT)n repeats display a higher degree of homology to the topoisomerase II consensus sequence, with a maximum matrix mean of 0.318. Cleavages were performed on a fragment containing a 25 base (GT)n repeat (TGC(GT)1I) from the fifth intron of the mouse thymidylate synthetase gene (29) ; the results are shown in Figure 5 (panel A shows cleavages on the (GT)n strand and panel B shows cleavages on the opposite, (AC)n strand). Cleavage sites on the actual sequence are indicated in Table 3 . Again, the RY repeat contained a cluster of strong topoisomerase II cleavage sites, and these sites were essentially identical whether no drug, m-AMSA, or VM26 was included in the reaction. Comparison of panels A and B shows that all of the RY repeat cleavage sites appeared symmetric (i.e. relatively equal frequencies of cleavage on both strands of a site), as shown in Table 3 . Consensus homology scores across the RY repeat reveal that the cleavage sites possessed the best matches (refer to Table 3 ). The most frequently cleaved site scored a matrix mean of 0.344 (which is fortuitously higher than a pure GT repeat due to non-GT flanking sequences). However, the cleavages in the RY repeat were, in general, stronger than the cleavages at some of the other sites in the fragment that had comparable scores (not shown); therefore, it appears that while the hierarchy of cleavage strengths within RY repeats is proportional to the matches to the topoisomerase II consensus sequence, the enzyme may be more reactive at sites containing alternating purine-pyrimidine sequences as compared to sites lacking them.
Topoisomerase II cleavages were also performed on a DNA fragment containing the HSV-1 origin of replication (which contains an (AT)6 repeat); the results are shown in Figure 6 . The only strong cleavages by the enzyme (plus or minus drugs) were within the RY repeat. The cleavage sites were nearly the same whether or not inhibitors were included, the only differences being at the 3' end of the fragment (top of the gel). The intense cleavage bands observed in the RY repeat were predicted to be recognition sites by matches of those sites to the topoisomerase Fig. 5 and Table 3 ). The strongest RY repeat site in Fig. 5 Fig. 1 ). Similar results were seen when the analysis was repeated using alkaline agarose gels (data not shown). This single strong band is composed of clustered proximal cleavage sites observed on sequencing gels with end labeled DNA (Fig. 2) T IG T IG T IG T IG T IG TIG T G T IG T G T IG T of the enzyme for RY repeats is proportional to the length of the repeats; as noted above with SV40 (Fig. 3) , all tested plasmids containing RY repeats were cleaved within the repeats, yet cleavages in shorter repeats were not as strong and were not the exclusive sites when compared to all sites within the plasmid domain.
The cleavage sites in supercoiled and relaxed pRYG were not significantly different either in location or intensity of cleavage. Interpretation of such an experiment is complicated because under the conditions optimal for cleavage, the enzyme will relax the supercoiled substrate and any difference between relaxed and supercoiled DNA is quickly eliminated as DNA linking numbers reach equilibrium. Even in the absence of ATP (in which case linking numbers cannot re-equilibrate) there were no detectable differences in cleavage patterns at RY sites in supercoiled or relaxed DNA (data not shown). These findings were surprising given the fact that RY repeats can adopt non-B DNA structures under conditions of superhelical tension. For example, the RY repeat in pCGTA-C adopts a Z DNA conformation when supercoiled (28) . We have also found that pRYG adopts an unusual conformation when supercoiled (Chung and Muller, unpublished data) but because of its sequence (mostly AT), a cruciform structure may be more likely than Z DNA (13) . Additionally, formation of non-covalent topoisomerase HI/DNA complexes are favored on supercoiled DNA (35) and eukaryotic topoisomerase I also is significantly more reactive toward negatively supercoiled DNA (36) . There are a number of possibilities as to why relaxed and supercoiled pRYG gave the same cleavage results. The enzyme might cleave an altered DNA conformation as efficiently as B DNA. Topoisomerase II binding might alter the conformation of an RY repeat to a B DNA form (either locally or from a distance). Since DNA conformation is dynamic, the enzyme may simply bind sequences when the equilibrium shifts towards a B DNA form. Additional studies are in progress to address this problem.
Effects of topoisomerase II inhibitors on cleavage within RY repeats Drugs such as VM26 and m-AMSA are often used to stimulate cleavage events by topoisomerase II, particularly for in vivo experiments (27, 32, 33) . A major concern about use of these drugs is whether they alter the specificity of the enzyme. We addressed this question previously (11) and found that 75% of all sites identified in the presence of m-AMSA or VM26 were also topoisomerase II sites in the absence of drugs. Additionally, we have found that sites identified in the absence of inhibitors are indistinguishable from sites identified in the presence of m-AMSA in terms of their match to the same consensus sequence (Spitzner and Muller, submitted). Thus, in most cases, the inclusion of m-AMSA does not alter the specificity of topoisomerase II at strong cleavage sites and similar results have been reported by other investigators (35) . We addressed this question for specific examples by analyzing all of the RY repeat cleavages both in the absence and presence of inhibitors. On a case by case basis one finds that both m-AMSA and VM26 may modify the site locations or, more often, the frequencies of topoisomerase II cleavage on a given DNA fragment, and the effect is more pronounced for VM26 than for m-AMSA. However, while the drugs caused some variations in cleavage by the enzyme, neither drug affected the general trend we are reporting in this paper, namely, the significant reactivity of topoisomerase H at alternating purine-pyrimidine sequences.
In vivo considerations RY repeats have been shown to be highly recombinagenic in vivo both in prokaryotes (14, (16) (17) (18) (19) and in eukaryotes (22, 23) . Additionally, proteins from several eukaryotic systems have been identified which specifically bind certain RY repeats that can end-labeling were performed as described previously (27) .
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Plasmids pRYG is a pUC19 derivative in which the 206 bp SphINarn fragment was replaced with the 245 bp SphI-AccI fragment upstream of the human 3-globin promoter; this insert contains a 54 bp alternating purine-pyrimidine repeat (see sequence in Table 2 ). The Z DNA forming plasmid pCGTA-C is described elsewhere (28 Table 4 ) than by using conventional consensus sequence comparisons (Spitzner and Muller, submitted Table 4 ; the enzyme cut site is between positions -1 and + 1, with minus positions 5' and plus positions 3' of the cut site. First, the (arbitrarily chosen) 'top strand' is analyzed. The base at the -10 position (10 bases 5' of the cleavage site) is examined and given the proportion value of that base in the matrix; in the (AT)n sequence in Table 4 , the -10 position is an A, which scores 0.423. Next, the -9 position contained (in the original data base) essentially a random distribution of nucleotides, so it is ignored (no score). The -8 position is an A and this matches 0.141 in the matrix. The -7 and -6 positions are ignored and the -5 T is given the value of the -5 T in the matrix, 0.197. After the matrix values have been determined for each of the 10 nonzero positions in the matrix, the same operation is performed for the bottom strand of the cleavage site, 4 bases 5'. The same base proportion matrix is used and is aligned 5' to 3' along the bottom strand. The matrix values are determined for each of the 10 nonzero positions as above; in this example ( 
